Product Information
CYCLOBENZAPRINE 5 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.0220 per EA under NDC 72888001200. Its NADAC has been published 210 times since Sep 28, 2022.
FDA first approved this application on May 31, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888001200
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CYCLOBENZAPRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208170FDA Approved
5/31/2017
TE Code
AB
On Market Since
5/31/2017
Pharmacological Classes
Price Statistics
The NADAC for CYCLOBENZAPRINE 5 MG TABLET has been published 210 times since Sep 28, 2022, and over the history we have for it it has declined 12.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0220 per EA |
|---|---|
| All-time high | $0.0284 (Nov 16, 2022) |
| All-time low | $0.0157 (Nov 20, 2024) |
| 52-week high | $0.0220 |
| 52-week low | $0.0209 |
| Median price | $0.0219 |
| Average price | $0.0220 |
| Largest weekly change | +36.3% (Aug 21, 2024) |
| Weeks tracked | 210 |
| Tracking since | Sep 28, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclobenzaprine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Muscle Relaxant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOBENZAPRINE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOBENZAPRINE 5 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.0220 per EA (NDC 72888001200), effective Sep 30, 2026.
How has the price of CYCLOBENZAPRINE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for CYCLOBENZAPRINE 5 MG TABLET has declined 12.5%. It has been tracked across 210 weekly CMS publications since Sep 28, 2022.
What are the highest and lowest recorded NADAC prices for CYCLOBENZAPRINE 5 MG TABLET?
Since Sep 28, 2022, the NADAC for CYCLOBENZAPRINE 5 MG TABLET has ranged from a low of $0.0157 (Nov 20, 2024) to a high of $0.0284 (Nov 16, 2022), with a median of $0.0219 per EA.
Are there cheaper alternatives to CYCLOBENZAPRINE 5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CYCLOBENZAPRINE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CYCLOBENZAPRINE 5 MG TABLET?
CYCLOBENZAPRINE 5 MG TABLET (NDC 72888001200) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.